Clinical trials: Epirubicin
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Diffuse Large B Cell Lymphoma
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma…
- Trial name
- NCT05887726
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Cancer
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear.
- Trial name
- NCT02115204
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 2,011 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TavIx (NCT00630032)
- Testing
- cyclophosphamide, Docetaxel, epirubicin hydrochloride
- Where
- 86 sites in United States, Belgium and 1 more
- Volunteers
- 762 people
- Sponsor
- UNICANCER
Gastric Cancer
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer.
- Trial name
- NCT00123318
- Testing
- epirubicin, cisplatin, 5-fluorouracil
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 52 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Breast Cancer
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B, premenopausal breast cancer patients stage II-IIIA.
- Trial name
- GIADA (NCT04659551)
- Testing
- Epirubicin, Cyclophosphamide, Triptorelin
- Where
- 5 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Diffuse Large B-Cell Lymphoma, POOR PROGNOSIS
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as first line treatment in young patients with…
- Trial name
- DLBCL (NCT00556127)
- Testing
- Rituximab, Epirubicin, Cyclophosphamide
- Where
- 14 sites in Italy
- Volunteers
- 94 people
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Breast Cancer
Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients
This is an adjuvant, open, prospective, randomized study to compare: A. Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel…
- Trial name
- PANTHER (NCT00798070)
- Testing
- dtEC→dtT, FEC→T
- Where
- 80 sites in Austria, Germany and 1 more
- Volunteers
- 2,017 people
- Sponsor
- Karolinska University Hospital
Breast Cancer
A Study for the Neoadjuvant Treatment of Breast Cancer
Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now.
- Trial name
- NCT05420454
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 1,576 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Cancer
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00057980
- Testing
- celecoxib, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Breast Cancer
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of…
- Trial name
- NCT06500208
- Testing
- Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Patients With Advanced or Metastatic Solid Tumors
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
The goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors.
- Trial name
- NCT02867397
- Testing
- Teysuno (S1) in combination with epirubicin and oxaliplatin
- Volunteers
- 25 people
- Sponsor
- Disphar International B.V.
Breast Cancer
The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647280
- Testing
- Abraxane, Epirubicin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Triple Negative Breast Neoplasms
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer.
- Trial name
- NCT04335669
- Testing
- epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
- Where
- 24 sites in Denmark, Sweden
- Volunteers
- 325 people
- Sponsor
- Lund University Hospital
HER2-negative Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04836156
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005583
- Testing
- cisplatin, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 23 sites in Belgium, France and 9 more
- Volunteers
- 400 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Breast Cancer, Neutropenia
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Conditions
- Breast Cancer, Neutropenia, Febrile Neutropenia
- Trial name
- NCT01611051
- Testing
- Drug: Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, rhG-CSF 5ug/kg/day
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Neoplasm
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients: trastuzumab (Herceptin) epirubicin…
- Trial name
- NCT00270894
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Accelerated Community Oncology Research Network
HER2+ Breast Cancer
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer.
- Trial name
- NCT05931042
- Testing
- Trastuzumab
- Where
- Pakistan
- Volunteers
- 1,209 people
- Sponsor
- Rawalpindi Medical College
Triple Negative Breast Cancer
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative…
- Trial name
- NeoTENNIS (NCT04418154)
- Testing
- epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University